Gene expression profile testing increasing in breast cancer

Gene expression profile testing increasing in breast cancer

(HealthDay) -- From 2006 to 2008, the use of gene expression profile (GEP) testing increased, correlating with a decrease in the percentage of women with hormone receptor (HR)-positive breast cancer receiving adjuvant chemotherapy, according to a study published online May 14 in the Journal of Clinical Oncology.

Michael J. Hassett, M.D., M.P.H., of the Dana-Farber Cancer Institute in Boston, and colleagues conducted a prospective study that assessed GEP testing and its association with subsequent chemotherapy use in 7,375 women diagnosed with HR-positive from 2006 to 2008 at 17 cancer centers.

The researchers found that, of the total participants, 20.4 percent received GEP testing and 50.2 received chemotherapy. From 2006 to 2008, GEP testing increased significantly, from 14.7 to 27.5 percent, and chemotherapy use decreased significantly, from 53.9 to 47.0 percent. The likelihood of testing was lower for African-American versus white women (odds ratio [OR], 0.70) and for those with high school or less versus more than high school education (OR, 0.63). Testing correlated with significantly decreased odds of chemotherapy use overall (OR, 0.70). In stratified analyses, testing correlated with increased odds of chemotherapy use in small, node-negative cancers (OR, 11.13), and with lower odds of chemotherapy use for node-positive and large, node-negative cancers (OR, 0.11).

"Our findings suggest that GEP testing may be associated with a change in the type of patients who receive chemotherapy and with the omission of chemotherapy for those unlikely to benefit," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

add to favorites email to friend print save as pdf

Related Stories

Adjuvant therapy shows promise in biliary tract cancer

Apr 27, 2012

(HealthDay) -- For patients with biliary tract cancers, postresection adjuvant therapy with chemotherapy or chemoradiotherapy appears to be beneficial in treating patients with biliary tract cancers, with ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

1 hour ago

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

4 hours ago

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

Immunotherapy set to revolutionise cancer treatment

6 hours ago

Immunotherapy is set to revolutionise the treatment of cancer, according to ESMO President Professor Rolf A. Stahel. His comments come as the ESMO Symposium on Immuno-Oncology 2014 is about to open in Geneva, Switzerland ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.